日本語 
Stallergenes Greer, together with Shionogi & Co., Ltd. and CEOLIA Pharma Co., Ltd. CEOLIA announced a change in the promotion of Actair®. This sublingual immunotherapy tablet is made by Stallergenes Greer. It treats allergic rhinitis from house dust mites in Japan.
Stallergenes Greer has appointed CEOLIA as its new promotional partner, starting July 3. This change comes after the end of its licensing agreement with Shionogi. The agreement started in 2010. It covered the development, registration, and commercialization of Actair® in Japan.
Shionogi will keep its role as the Marketing Authorisation Holder (MAH) in Japan for a set time. This will help provide smooth care for patients and support for healthcare workers during the transition. Shionogi will keep managing the import, production, and distribution of Actair®. They will also help CEOLIA by sharing knowledge and providing operational support.
Also Read: Alpha Fusion, Curadh MTR Partner on Astatine-211 Drugs
Stallergenes Greer thanked Shionogi & Co for its long support in allergy care in Japan. They also welcomed CEOLIA as a new trusted partner. The company is excited to work with CEOLIA Pharma. Together, they will expand access to allergen immunotherapy. This partnership aims to improve the quality of life for patients with respiratory allergies.
English